|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.98 USD | -0.96% |
|
-4.33% | -17.80% |
| Mar. 11 | Legend Biotech Shares Likely to Rebound in 2026 on Robust Fundamentals, RBC Says | MT |
| Mar. 11 | RBC Cuts Price Target on Legend Biotech to $62 From $66, Keeps Outperform Rating | MT |
Company Valuation: Legend Biotech Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 7,175 | 8,357 | 10,938 | 5,969 | 4,015 | 3,359 | - | - |
| Change | - | 16.46% | 30.89% | -45.43% | -32.74% | -16.35% | - | - |
| Enterprise Value (EV) 1 | 6,446 | 7,855 | 9,959 | 4,496 | 3,480 | 2,513 | 2,229 | 1,764 |
| Change | - | 21.86% | 26.78% | -54.85% | -22.6% | -27.8% | -11.3% | -20.86% |
| P/E ratio | -17x | -17.8x | -20.5x | -33.9x | -13.4x | 293x | 16.2x | 10.2x |
| PBR | 15.3x | - | 8.75x | 5.74x | 4.01x | 3.13x | 2.47x | 1.84x |
| PEG | - | -8.13x | -4.1x | 0.5x | -0.2x | -3x | 0x | 0.2x |
| Capitalization / Revenue | 79.9x | 71.4x | 38.4x | 9.52x | 3.9x | 2.34x | 1.84x | 1.58x |
| EV / Revenue | 71.8x | 67.1x | 34.9x | 7.17x | 3.38x | 1.75x | 1.22x | 0.83x |
| EV / EBITDA | -17.9x | -17.7x | -25.4x | -39.7x | -15x | 20.2x | 6.03x | 2.96x |
| EV / EBIT | -17.3x | -17.2x | -24.1x | -32.9x | -13.3x | 34.3x | 6.18x | 3.21x |
| EV / FCF | -26.6x | -33.1x | -24.1x | -28.4x | -27x | 18.7x | 5.35x | 2.78x |
| FCF Yield | -3.76% | -3.02% | -4.15% | -3.52% | -3.7% | 5.35% | 18.7% | 35.9% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.74 | -2.8 | -2.94 | -0.96 | -1.62 | 0.062 | 1.12 | 1.776 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 89.79 | 117 | 285.1 | 627.2 | 1,029 | 1,435 | 1,828 | 2,119 |
| EBITDA 1 | -360.6 | -443.2 | -392.1 | -113.2 | -232.2 | 124.2 | 369.5 | 596.3 |
| EBIT 1 | -373 | -455.8 | -412.6 | -136.5 | -261.2 | 73.34 | 360.8 | 550.2 |
| Net income 1 | -386.2 | -446.3 | -518.3 | -177 | -296.8 | 66.57 | 318.2 | 499.4 |
| Net Debt 1 | -729.5 | -501.5 | -979.4 | -1,473 | -534.9 | -846 | -1,130 | -1,595 |
| Reference price 2 | 46.61 | 49.92 | 60.17 | 32.54 | 21.74 | 18.16 | 18.16 | 18.16 |
| Nbr of stocks (in thousands) | 153,946 | 167,403 | 181,789 | 183,451 | 184,690 | 184,943 | - | - |
| Announcement Date | 3/18/22 | 3/30/23 | 3/11/24 | 3/11/25 | 3/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 292.9x | 1.75x | 20.22x | -.--% | 3.36B | |
| 27.95x | 7.4x | 22.05x | 0.05% | 49.79B | |
| 18.25x | 5.44x | 12.35x | 1.62% | 46.97B | |
| -59.72x | 19.31x | -65.3x | -.--% | 33.42B | |
| -18.17x | 4.01x | -7.52x | -.--% | 24.15B | |
| 28.54x | 5.58x | 15.51x | -.--% | 18.97B | |
| 23.1x | 4.04x | 12.35x | -.--% | 17.25B | |
| -393.24x | 32.84x | 1807.92x | -.--% | 16.25B | |
| -15.77x | 1757.99x | -21.98x | -.--% | 15.25B | |
| -205.97x | 50.1x | -198.99x | -.--% | 14.68B | |
| Average | -30.21x | 188.85x | 159.66x | 0.17% | 24.01B | |
| Weighted average by Cap. | -32.98x | 123.41x | 108.38x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- LEGN Stock
- Valuation Legend Biotech Corporation
Select your edition
All financial news and data tailored to specific country editions
